Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
January 2008
Features
Impact of Bipolar Disorder on the Family: Utilization and Cost of Health Care Resources
The authors describe a study in which “bipolar families,” compared with families without a serious mental illness, incurred much higher medical costs, visited physicians more often, had more hospital stays, and spent more money on prescription drugs.
Mary Lou Chatterton, PharmD, Xiongkan Ke, MS, Barbara Edelman Lewis, PhD, MHA, Krithika Rajagopalan, PhD, and Arthur Lazarus, MD, MBA
Case Report
Aripiprazole (Abilify) and Tardive Dyskinesia
Second-generation atypical antipsychotic drugs carry a lower risk of extrapyramidal symptoms and tardive dyskinesia compared with conventional agents, but they are not without their dangers. The case report of a 46-year-old patient demonstrates the point that the newer agents should be used according to their FDA-approved indications, when possible, and that patients using aripiprazole, an “atypical atypical” agent, need to be carefully monitored.
Thomas Schwartz, MD, and Shafi Raza, MD
Advances in Vaccine Technology and Their Impact On Managed Care
Although the “vaccine revolution” has resulted in products that can prevent illness and reduce costs of disease, the authors raise several concerns: who will pay for these improvements, how these advances will alter treatment, how cost and efficacy will be balanced, and how to choose the right product.
Jonathan A. McCullers, MD, and Jeffrey D. Dunn, PharmD, MBA
Meeting Highlights
American Heart Association, 2007 Scientific Sessions
Presentations cover a number of clinical trials of cardiac agents, including clopidogrel versus prasugrel; an investigative thrombin receptor antagonist; a niacin/simvastatin combination; warfarin dosing versus genotype-guided dosing; clopidogrel eptifibatide, and bivalirudin; and eptifibatide versus abciximab.
Walter Alexander
Pharmaceutical Approval Update
Topics include nilotinib (Tasigna Capsules) for the treatment of chronic myelogenous leukemia (CML), raltegravir (Isentress) for patients with HIV-1 infection, and ixabepilone (Ixempra), combined with capecitabine (Xeloda), for use in metastatic or locally advanced breast cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
Better
David Nash, MD, MBA, reviews Better: A Surgeon’s Notes on Performance, a book in which Dr. Atul Gawande asserts that our health care system won’t improve until we rethink our everyday practices.
David Nash, MD, MBA
Medication Errors
Safety and Patient-Controlled Analgesia Part 2: How to Prevent Errors
In Part 2 of a two-part series, Matthew Grissinger, RPh, FASCP, details the steps needed for safely prescribing and dispensing patient-controlled analgesia (PCA).
Matthew Grissinger, RPh, FASCP
Prescription: Washington
FDA Considers New Avenue for Pharmacist Reimbursement
Stephen Barlas discusses how consumers might have access to a number of “behind-the-counter” drugs only after they are counseled by a pharmacist.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
From cephipeme to valsartan, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Dalbavancin (Zeven), a Novel Glycopeptide for Resistant Gram-Positive Organisms
Drs. Colabella and Chagan review dalbavancin (Zeven), a glycopeptide for resistant gram-positive organisms.
Jennifer Colabella, PharmD, and Larisa Chagan, PharmD, BCPS
